LWP
VRTX icon

Lumature Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Lumature Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-28
Closed -$7K – 442
2022
Q1 		$7K Sell
28
-27
-49% -$6.41K ﹤0.01% 365
2021
Q4 		$12K Sell
55
-35
-39% -$6.81K ﹤0.01% 320
2021
Q3 		$16K Sell
90
-27
-23% -$5.27K 0.01% 315
2021
Q2 		$24K Buy
117
+3
+3% +$628 0.01% 258
2021
Q1 		$24K Sell
114
-1,174
-91% -$258K 0.01% 258
2020
Q4 		$304K Buy
+1,288
New +$296K 0.29% 100

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Lumature Wealth Partners's VRTX Position: Q2 2022 in Review

Lumature Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 28 shares — an estimated $7K sold.

Lumature Wealth Partners first reported a position in VRTX in Q4 2020 and held it in 6 quarters. The position peaked at $304K in Q4 2020. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Lumature Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Lumature Wealth Partners sold 28 Vertex Pharmaceuticals shares in Q2 2022, an estimated $7K.
  • Lumature Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Lumature Wealth Partners's Vertex Pharmaceuticals position peaked at $304K in Q4 2020.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Lumature Wealth Partners's 13F filing for Q2 2022, filed 10 Aug 2022.